PRXL

AstraZeneca’s Phase III Study on NSCLC: A Potential Game-Changer

PremiumCompany Announcements

1d ago

AstraZeneca’s New Colorectal Cancer Study: A Potential Game-Changer?

PremiumCompany Announcements

3d ago

AstraZeneca’s Phase III NSCLC Study: A Potential Game-Changer?

PremiumCompany Announcements

3d ago

AstraZeneca’s Bioavailability Study of AZD5004: Key Insights for Investors

PremiumCompany Announcements

5d ago

PremiumCompany AnnouncementsParexel’s Peanut Allergy Study: A Potential Game-Changer in Allergy Treatment

5d ago

AstraZeneca’s New Study Explores Drug Interactions with Food and Inhibitors

Company Announcements

AstraZeneca’s New Study Explores Drug Interactions with Food and Inhibitors

8d ago

AstraZeneca’s Promising Phase II Study on NSCLC Treatment

Company Announcements

AstraZeneca’s Promising Phase II Study on NSCLC Treatment

8d ago

AstraZeneca’s Latest Study: Exploring Drug Interactions and Market Implications

PremiumCompany Announcements

8d ago

AstraZeneca’s Latest Study on Ceralasertib: What Investors Need to Know

PremiumCompany Announcements

8d ago

AstraZeneca’s Phase I Study of AZD1163: A Key Update for Investors

PremiumCompany Announcements

9d ago

AstraZeneca’s AZD2389 Study: Key Insights for Investors

PremiumCompany Announcements

9d ago

PremiumCompany AnnouncementsAstraZeneca’s Phase III Study on Anifrolumab for Cutaneous Lupus Erythematosus: Key Insights for Investors

9d ago

Parexel’s Clinical Study Update: A New Hope for HER2+ Breast Cancer Treatment

Company Announcements

Parexel’s Clinical Study Update: A New Hope for HER2+ Breast Cancer Treatment

9d ago

AstraZeneca’s New Study: Food and Drug Interactions Under the Microscope

Company Announcements

AstraZeneca’s New Study: Food and Drug Interactions Under the Microscope

10d ago

AstraZeneca’s Latest Study on NSCLC Treatment: A Potential Game-Changer?

PremiumCompany Announcements

10d ago

AstraZeneca’s Phase I Study of AZD1163: A Key Update for Investors

PremiumCompany Announcements

11d ago